Summary: In patients with predominantly intermediate-risk differentiated thyroid cancer (DTC), recombinant human thyrotropin (rhTSH) with 3.7 GBq of radioactive iodine…
Browsing: PICO
Summary: In adults with type 2 diabetes participating in the SURPASS-2 phase 3 trial across multiple countries, once-weekly subcutaneous tirzepatide…
Summary: In healthy adult women participating in two pooled randomized trials investigating thyroid function biomarkers during sleep restriction (SR), prolonged…
Summary: In healthy adult participants, including Japanese and non-Japanese individuals, single-dose administration of cilofexor and firsocostat significantly resulted in higher…
Summary: In adults with type 2 diabetes and chronic kidney disease, stratified by baseline use of SGLT2 inhibitors, weekly administration…
Summary: In adults aged 18 or older with obesity and prediabetes, once-weekly subcutaneous semaglutide 2.4 mg combined with diet and…
Summary: In adults with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide 2.4 mg administered weekly for 52 weeks…
Summary: In healthy Chinese adults, once-daily oral semaglutide (3 mg escalating to 14 mg over 12 weeks) significantly reduced body…
Summary: In adults with overweight or obesity participating in the STEP 1-4 Phase 3a trials over 68 weeks, once-weekly semaglutide…
Summary: In adults with preexisting cardiovascular disease, overweight or obesity, and no prior diagnosis of diabetes, semaglutide (GLP-1 receptor agonist)…